Skip to main content
SpringerLink
Log in

Defining rewardable innovation in drug therapy

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Implementing mechanisms for rewarding those who introduce innovative medicinal products requires a definition of 'rewardable innovation'. Here, we propose a definition of innovation with respect to medicinal products, accompanied by a ranking of the importance of different types of innovativeness, with the aim of providing a basis for rewarding such innovation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ferner, R. E., Hughes, D. A. & Aronson, J. K. NICE and new: appraising innovation. BMJ 340, b5493 (2010).

    Article  Google Scholar 

  2. Office of Fair Trading. Annexe L: Evaluation of options for reform to the PPRS. Office of Fair Trading website [online], (2007).

  3. Kennedy, I. Appraising the value of innovation and other benefits. A short study for NICE. NICE website [online], (2009).

    Google Scholar 

  4. Aronson, J. K. Something new every day: defining innovation and innovativeness in drug therapy. J. Ambul. Care Manage. 31, 65–68 (2008).

    Article  Google Scholar 

  5. Hughes, D. A. Value-based pricing: incentive for innovation or zero net benefit? Pharmacoeconomics 29, 731–735 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jeffrey K. Aronson is at the Department of Primary Health Care, University of Oxford, 23–38 Hythe Bridge Street, Oxford OX1 2ET, UK.,

    Jeffrey K. Aronson

  2. Robin E. Ferner is at the West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham B18 7QH, UK, and the School of Clinical and Experimental Medicine, University of Birmingham, B15 2TT, UK.,

    Robin E. Ferner

  3. Dyfrig A. Hughes is at the Centre for Health Economics and Medicines Evaluation, Bangor University, Dean Street, Bangor LL57 1UT, UK.,

    Dyfrig A. Hughes

Authors
  1. Jeffrey K. Aronson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin E. Ferner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dyfrig A. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jeffrey K. Aronson, Robin E. Ferner or Dyfrig A. Hughes.

Ethics declarations

Competing interests

J.K.A. is President Emeritus of the British Pharmacological Society, and a member of the Technology Appraisal Committee of the UK National Institute for Health and Clinical Excellence (NICE). R.E.F. is an NHS member of the NICE Appeal Panel. D.A.H. is a member of the Welsh Medicines Partnership. However, the opinions expressed here are not necessarily shared by other members of those organizations or the organizations themselves.

Supplementary information

Supplementary table 1

Features relevant to a definition of rewardable innovation and their inclusion in previous definitions (PDF 159 kb)

Supplementary table 2

The usefulness of therapeutic innovations from different perspectives (PDF 123 kb)

Supplementary table 3

Innovative features of a selection of beta-blockers (PDF 132 kb)

Supplementary table 4

Varieties of innovativeness ranked by degree (adapted from reference 1) (PDF 149 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aronson, J., Ferner, R. & Hughes, D. Defining rewardable innovation in drug therapy. Nat Rev Drug Discov 11, 253–254 (2012). https://doi.org/10.1038/nrd3715

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3715

  • Springer Nature Limited

This article is cited by

Search

Navigation